{
    "nctId": "NCT02763007",
    "officialTitle": "An Extension Study of Protocol ALO-IIT(PEAK Study) to Examine the Long-term Efficacy and Safety of Metformin + Alogliptin + Pioglitazone Triple Combination Therapy in the Korean Type 2 Diabetes Patients",
    "inclusionCriteria": "* Completed \"ALO-IIT-012(PEAK study)\", without major protocol deviations.\n* Male, or female, 19 years to 75 years.\n* Female with childbearing potential who has a negative urine pregnancy test result at study start and willing to continue practice appropriate birth control during the entire duration of study\n* Subjects completed PEAK can be included within 30 days after End Of the Study\n* Subjects completed PEAK can be included if their treatment is the same as randomized even after 30 days of End Of the Study.\n* Must have minimum age of 19 Years\n* Must have maximum age of 75 Years",
    "exclusionCriteria": "* eGFR(Epidermal growth factor receptor) \\< 50mL/min\n* AST(aspartate aminotransferase)/ALT(alanine aminotransaminase) \\>2.5 upper limit of normal\n* Pregnant or lactating women\n* Subject who the investigator deems inappropriate to participate in this study\n* Patients with a history of bladder cancer or patients with active bladder cancer\n* Patients with uninvestigated macroscopic hematuria\n* Patients with cardiac failure or a history of cardiac failure (New York Heart Association \\[NYHA\\] Stages 3 to 4)\n* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, since this study drug contains lactose"
}